Positioning of Esketamine Treatment in the Real-world Management of Depression

Open-label, single-group study of intranasal esketamine administered under supervision as an add-on to ongoing antidepressant treatment across acute (weeks 1–4), maintenance (weeks 5–8) and continuation (weeks 9–25) phases.

Primary aims are to evaluate effectiveness of esketamine in real-world practice and to identify patient characteristics associated with therapeutic response; participants are observed for two hours after dosing with blood pressure monitoring and complete questionnaires and reassessments for dose adjustment.